Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Investor Group Buys INO Therapeutics

March 5, 2007 | A version of this story appeared in Volume 85, Issue 10

An investor group will acquire INO Therapeutics from Linde and combine it with the two-year-old biotech firm Ikaria. The group values the transaction at $670 million. INO, a supplier of gaseous drugs including nitric oxide, has annual revenues of $160 million. Ikaria is pursuing research and development on metabolic control via hydrogen sulfide. The investor group expects to inject an additional $300 million into the new firm, called Ikaria Holdings, to develop gaseous drugs to treat chronic lung disease in premature newborns and myocardial infarction, ischemic stroke, and other diseases in adults.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.